Jade Homsi
Overview
Explore the profile of Jade Homsi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
51
Citations
1780
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Park S, Ellison D, Weight R, Homsi J, Rabinowits G, Ruiz E, et al.
Future Oncol
. 2025 Jan;
21(4):431-436.
PMID: 39797702
Patients diagnosed with metastatic basal cell carcinoma (BCC) have a poor prognosis. The current standard of care for adults with locally advanced or metastatic BCC who are not candidates for...
2.
Song B, Wang K, Na S, Yao J, Fattah F, von Itzstein M, et al.
bioRxiv
. 2024 Jul;
PMID: 39005456
The interaction between antigens and antibodies (B cell receptors, BCRs) is the key step underlying the function of the humoral immune system in various biological contexts. The capability to profile...
3.
von Itzstein M, Yang Y, Wang Y, Hsiehchen D, Sheffield T, Fattah F, et al.
Front Immunol
. 2024 May;
15:1351739.
PMID: 38690281
Background: A useful clinical biomarker requires not only association but also a consistent temporal relationship. For instance, chemotherapy-induced neutropenia and epidermal growth-factor inhibitor-related acneiform rash both occur within weeks of...
4.
Huang R, Liu X, Kim J, Deng H, Deng M, Gui X, et al.
Cancer Immunol Res
. 2023 Dec;
12(3):350-362.
PMID: 38113030
The existing T cell-centered immune checkpoint blockade therapies have been successful in treating some but not all patients with cancer. Immunosuppressive myeloid cells, including myeloid-derived suppressor cells (MDSC), that inhibit...
5.
Han Y, Yang Y, Tian Y, Fattah F, von Itzstein M, Hu Y, et al.
bioRxiv
. 2023 Dec;
PMID: 38105939
Profiling the binding of T cell receptors (TCRs) of T cells to antigenic peptides presented by MHC proteins is one of the most important unsolved problems in modern immunology. Experimental...
6.
Gross N, Miller D, Khushalani N, Divi V, Ruiz E, Lipson E, et al.
Lancet Oncol
. 2023 Oct;
24(11):1196-1205.
PMID: 37875144
Background: We previously reported rates of pathological complete responses (51% [95% CI 39-62] per independent central review, the primary endpoint) and major pathological responses (13% per independent central review, a...
7.
8.
Mundra V, Yang Y, von Itzstein M, Fattah F, Gonugunta A, Hannan R, et al.
Transl Oncol
. 2023 Jun;
34:101689.
PMID: 37285748
Introduction: Preclinical studies have demonstrated the ability of radiation therapy (RT) to augment immune response and tumor control by immune checkpoint inhibitors (ICI). However, numerous clinical trials combining RT and...
9.
von Mehren M, Kane J, Riedel R, Sicklick J, Pollack S, Agulnik M, et al.
J Natl Compr Canc Netw
. 2022 Nov;
20(11):1204-1214.
PMID: 36351335
Gastrointestinal stromal tumors (GIST) are the most common type of soft tissue sarcoma that occur throughout the gastrointestinal tract. Most of these tumors are caused by oncogenic activating mutations in...
10.
Gross N, Miller D, Khushalani N, Divi V, Ruiz E, Lipson E, et al.
N Engl J Med
. 2022 Sep;
387(17):1557-1568.
PMID: 36094839
Background: In a pilot study involving patients with cutaneous squamous-cell carcinoma, a high percentage of patients had a pathological complete response with the use of two doses of neoadjuvant cemiplimab...